Core Insights - Eli Lilly and Company reported a highly successful year in 2024, with significant revenue growth and strategic investments aimed at long-term growth [3][4][5] Financial Results - In Q4 2024, Eli Lilly's worldwide revenue reached $13.53 billion, a 45% increase from Q4 2023, driven by a 48% increase in volume, partially offset by a 4% decrease in realized prices [5][9] - Reported net income for Q4 2024 was $4.41 billion, a 101% increase compared to $2.19 billion in Q4 2023, with earnings per share (EPS) rising 102% to $4.88 [4][15] - Non-GAAP net income for Q4 2024 was $4.81 billion, a 114% increase from $2.25 billion in Q4 2023, with non-GAAP EPS increasing to $5.32 [18][19] Revenue Breakdown - New Products revenue grew by $3.15 billion to $5.64 billion in Q4 2024, led by Zepbound and Mounjaro [5][6] - Growth Products revenue increased 13% to $5.95 billion, driven by Verzenio and Jardiance, despite lower sales of Trulicity [5][6] - Mounjaro revenue increased 60% to $3.53 billion, with U.S. revenue at $2.63 billion, reflecting strong demand [20][21] - Zepbound, launched in November 2023, generated $1.91 billion in U.S. revenue for Q4 2024, compared to $175.8 million in Q4 2023 [24] Cost and Expenses - Gross margin for Q4 2024 increased 47% to $11.13 billion, with a gross margin percentage of 82.2%, up 1.3 percentage points [11][16] - Research and development expenses rose 18% to $3.02 billion, representing 22.3% of revenue, reflecting continued investment in the company's portfolio [11][12] - Marketing, selling, and administrative expenses increased 26% to $2.42 billion, driven by promotional efforts [12] 2025 Financial Guidance - Eli Lilly anticipates 2025 revenue between $58.0 billion and $61.0 billion, representing approximately 32% growth compared to 2024 [29][31] - Expected EPS for 2025 is in the range of $22.05 to $23.55 on a reported basis and $22.50 to $24.00 on a non-GAAP basis [31][33] - The company plans to continue investing in manufacturing capacity, estimating to produce at least 1.6 times the amount of salable incretin doses in the first half of 2025 compared to the first half of 2024 [29]

Financial Performance - Eli Lilly is set to release its fourth-quarter financial results on February 6, 2025, with expected earnings of $5.08 per share, a significant increase from $2.49 per share in the same quarter last year [1] - The company projects quarterly revenue of $13.43 billion, up from $9.35 billion a year earlier [1] Revenue Growth Expectations - For the full year 2024, Eli Lilly anticipates worldwide revenue to be approximately $45.0 billion, reflecting a 32% growth compared to the previous year, slightly below the consensus estimate of $45.50 billion [2] Stock Performance and Analyst Ratings - Eli Lilly shares increased by 2% to close at $842.18 [2] - Analysts have provided various ratings and price targets for Eli Lilly, with Wells Fargo maintaining an Overweight rating and reducing the price target from $1,000 to $970 [4] - B of A Securities reinstated a Buy rating with a price target of $997, while Barclays cut its price target from $1,025 to $975, both maintaining Overweight ratings [4] - Morgan Stanley reiterated an Overweight rating with a price target of $1,106, and BMO Capital raised its price target from $1,001 to $1,101 while maintaining an Outperform rating [4]

Core Viewpoint - Eli Lilly is set to report its fourth-quarter earnings, with Wall Street expecting an EPS of $4.94 and revenues of $13.66 billion, indicating strong market anticipation for the company's performance [1]. Stock Performance - Eli Lilly stock has shown a significant increase of 19.23% over the past year and 8.22% year-to-date [1]. - The current share price is $841.78, which is above the five-day, 20-day, and 50-day exponential moving averages, indicating strong bullish momentum [2]. - The stock has also crossed its 200-day simple moving average of $841.52, breaking resistance levels and signaling long-term bullish momentum [3]. Technical Indicators - The Moving Average Convergence Divergence (MACD) indicator is at 12.09, supporting a bullish outlook, while the Relative Strength Index (RSI) is at 64.87, suggesting the stock is nearing overbought territory but still has potential for further gains [3]. Analyst Ratings - The consensus analyst rating for Eli Lilly stock is a Buy, with a price target of $955.21, indicating a potential upside of 26.97% based on the latest ratings from Truist Securities, Wells Fargo, and Citigroup [5]. - At the time of publication, Eli Lilly stock was up 1.9% at $842.30 [5].

Core Viewpoint - Eli Lilly (LLY) is expected to report earnings soon, with the options market indicating significant anticipated movements in the stock price [1] Options Positioning - The options positioning for LLY has shifted from neutral to fully bullish as of now, with bulls targeting a major upside strike at $900 [3] - The largest open interest for February options shows 1,365 calls at the $800 strike, which is the top gamma strike (TGS) and indicates strong market consensus on this level [4][5] - There is a notable lack of put gamma above $800, suggesting that bulls may attempt to push the stock towards $900 if earnings exceed expectations [5] Option Flows - Recent option flows indicate a bullish sentiment, primarily driven by traders closing long puts and selling puts, which has provided a short-term boost to LLY's stock price [6] - On the call side, traders are taking profits by selling calls ahead of the earnings report, with more put selling than call selling contributing to the upward price movement [7] Price Action - The $800 TGS level has shown strong support, holding pullbacks multiple times since late January, indicating a solid base for potential upward movement [8] - The implied move for LLY's earnings is currently estimated at $45, which may adjust to around $37 after accounting for theta decay, suggesting potential price targets of approximately $860 or $788 post-announcement [9][11] Trading Strategy - The company has established a bullish position and may consider booking deep out-of-the-money puts as insurance, with plans to close positions if the stock rises significantly [12]

Core Insights - Eli Lilly (LLY) is anticipated to report fourth-quarter earnings, with expectations of increased sales and profits following the resolution of shortages for its weight-loss drugs [1][7] Financial Performance - Analysts project Eli Lilly will achieve $13.63 billion in revenue for the fourth quarter, representing a year-over-year increase of over 45% due to the success of its weight-loss drugs [3] - Net income is expected to more than double from the previous year to $4.58 billion, equating to $5.06 per share [3] Analyst Ratings - Among analysts tracking Eli Lilly, 10 out of 11 have rated the stock as a "buy," with one "hold" rating, and the average price target is nearly $986, indicating a 21% premium over recent trading levels [2] Sales Forecast Adjustments - The company had previously lowered its sales expectations for the fourth quarter, with anticipated revenue around $13.5 billion for the quarter and $45 billion for the full year [5][4] - CEO David Ricks indicated that production of salable doses of weight-loss drugs is expected to be 60% higher in the first half of this year compared to the same period in 2024 [5] Market Context - Eli Lilly and its competitor Novo Nordisk (NVO) have experienced demand consistently outpacing supply for their weight-loss drugs, with Lilly's products removed from the FDA's shortage list late last year [6] - Despite a recent decline from record levels, Eli Lilly shares have increased by over 20% in the past year [7]

Core Insights - Eli Lilly (LLY) is expected to report quarterly earnings of $5.15 per share, reflecting a significant increase of 106.8% year-over-year, with revenues projected at $13.48 billion, up 44.1% from the previous year [1] Earnings Estimates - The consensus EPS estimate has been revised down by 0.5% in the last 30 days, indicating a reassessment by analysts [2] - Revisions to earnings estimates are crucial indicators for predicting investor actions regarding the stock, with empirical research showing a strong correlation between earnings estimate trends and short-term stock performance [3] Key Metrics Forecast - Analysts predict 'Net Sales- Cyramza' to be $258.19 million, a year-over-year increase of 1.8% [5] - 'Net Sales- Humalog' is expected to reach $590.93 million, indicating a substantial increase of 61.2% from the prior year [5] - 'Net Sales- Forteo' is forecasted at $97.33 million, reflecting a decrease of 16.4% year-over-year [6] - 'Net Sales- Erbitux' is estimated at $153.10 million, showing a slight increase of 1.9% from the previous year [6] Geographic Revenue Projections - 'Net Sales- International-Humalog' is expected to be $212.76 million, up 6.9% year-over-year [7] - 'Geographic Revenue- United States' is projected to reach $9.48 billion, indicating a year-over-year increase of 46.9% [8] - 'Net Sales- Diabetes- Mounjaro -Outside U.S.' is forecasted at $1.08 billion, representing a remarkable increase of 978.2% from the prior year [9] Stock Performance - Shares of Eli Lilly have returned +3.7% over the past month, outperforming the Zacks S&P 500 composite, which increased by +2.7% [9]

Core Viewpoint - Eli Lilly, Novo Nordisk, and Vertex Pharmaceuticals are identified as long-term investment opportunities in the healthcare sector due to their strong growth prospects and innovative pipelines. Eli Lilly - Eli Lilly is characterized as a growth powerhouse with robust financials, a solid drug pipeline, and a growing dividend, making it a reliable long-term investment [2][3]. - The company anticipates revenue between $58 billion and $61 billion for 2025, reflecting a growth rate of 32% [3]. - Eli Lilly has a profit margin exceeding 20%, allowing for reinvestment into research and development [4]. - The company has doubled its dividend payout in five years, despite a payout ratio over 80%, which is expected to decrease as operations scale [5]. - The stock has appreciated 240% over the past three years, although it trades at more than 80 times earnings, which is considered justifiable given its growth potential [6]. Novo Nordisk - Novo Nordisk has faced recent challenges, but its strong financial results and innovative pipeline present a long-term investment opportunity [7][9]. - The company’s next-gen weight loss drug, CagriSema, achieved a mean weight loss of 22.7% in trials, slightly below expectations, impacting stock performance [8]. - Novo Nordisk continues to innovate, with promising results from a phase 1b/2a study for subcutaneous amycretin and recent approvals for new products [10][11]. - The company has a strong drug discovery engine that has historically dominated the diabetes market, positioning it for future growth [11]. Vertex Pharmaceuticals - Vertex Pharmaceuticals is the sole provider of therapies for cystic fibrosis, with recent approval of Alyftrek enhancing its product offerings [12]. - The company is expanding its focus beyond cystic fibrosis, developing non-opioid pain relief alternatives and targeting APOL1-mediated kidney disease [13]. - Vertex is also pursuing potentially curative therapies for type 1 diabetes, with two candidates in clinical development [14]. - The company has partnered with CRISPR Therapeutics to develop gene-editing therapies, showcasing its innovative capabilities [15].

Eli Lilly and Company (LLY) will report its fourth-quarter and full-year 2024 earnings on Feb. 6, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $13.72 billion and $5.15 per share, respectively. Earnings estimates for 2025 have declined from $24.05 to $23.57 per share over the past 30 days.Image Source: Zacks Investment ResearchFind the latest EPS estimates and surprises on Zacks Earnings Calendar.LLY’s Earnings Surprise HistoryThe healthcare bellwether’s performance ha ...

Over the past six months, Eli Lilly (LLY -1.48%) has underperformed broader equities. While that's not much of an issue in the grand scheme of things, it is still a bit surprising, since the pharmaceutical giant is one of the undisputed leaders in the exciting market for weight loss drugs.It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in lower-than-expected revenue for the company's famous weight management drug, Zepbound.That's one of the key ...

Company Overview - Eli Lilly and Company occupies over 40% of the fast-growing weight loss drug market [1] - The stock has been growing at a compound annual growth rate (CAGR) of over 30% since 2015, reaching an all-time high (ATH) in August [1] Analyst Insights - Daniel Sereda is the chief investment analyst at a family office, focusing on diverse asset classes and navigating extensive information daily [1] - The investing group Beyond the Wall Investing provides access to critical information prioritized by institutional market participants [1]